Cisplatin, Fluorouracil, Interferon-a, and Radiation asAdjuvant Therapy for Resected Pancreatic Cancer: Is There a

摘要

In this issue of Annals of Surgery, Linehan and colleagues from Siteman Cancer Center and Washington University School of Medicine report results of a single-institution phase II study of adjuvant cisplatin, fluorouracil (5-FU), and interferon-a-based chemo-radiation followed by gemcitabine for patients with resected pancreatic adenocarcinoma.1 With a median follow-up of 38 months, the authors report a median overall survival of 25 months and actuarial 1-, 2-, and 3-year overall survival rates of 75%, 56%, and 41%, respectively. These results and additional emerging data on the regimen2'3 bring to light several issues for further consideration: 1) patient selection (selection bias), 2) toxicities of this adjuvant treatment regimen, 3) outcome data in combination with other trials evaluating this regimen, and 4) the thorny issue of whether this regimen is worthy of further study and, if so, in what setting